PTGS2 and primary cutaneous T-cell non-Hodgkin lymphoma: Take the Cutaneous T-cell lymphomas (CTCL) as an example, COX-2 expression has recently been proven in CTCL cells, and treatment with the selective COX-2 inhibitor celecoxib resulted in decreased cell growth and viability [66].